⚠ Evidence note: Exercise has the strongest human evidence base in this vault, but protocol-level specifics are far less settled than the headline benefit.
Sarcopenic Obesity
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-11-09 — Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes: [expert-opinion] A 24-week clinical trial description (no results supplied) evaluates exercise plus daily whey protein for muscle-volume and functional preservation during semaglutide or tirzepatide initiation in adults with type 2 diabetes, without establishing prevention of consensus-defined sarcopenic obesity or confirming that participants have that phenotype. [expert-opinion] (novelty: 3)
- 2026-11-11 — Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.: [human-rct] COURAGE, a two-part phase 2 double-blind, placebo-controlled randomized trial (n=975) in adults with obesity receiving semaglutide, found that trevogrumab attenuated lean-mass loss with reported good tolerability, whereas adding garetosmab further improved body composition but caused unacceptable adverse events; these body-composition findings do not establish improved strength, physical function, or prevention of consensus-defined sarcopenic obesity. [human-rct] (novelty: 4)
- 2026-11-12 — Will sarcopenia preventative pharmacology ensure the long-term success of GLP-1-derived therapies?: [expert-opinion] Review proposes sarcopenia-preventative pharmacology as a potential adjunct to GLP-1-derived weight-loss therapies, without establishing that lean-mass loss constitutes sarcopenia or that adjunctive drugs are necessary for long-term metabolic or functional benefit. [expert-opinion] (novelty: 3)
- 2026-11-10 — Associations between sarcopenic obesity subtypes, cognitive function and neurodegenerative diseases risk in middle-aged and older adults.: [human-observational] Observational CHARLS cohort analysis using latent class analysis identified three sarcopenic-obesity subtypes, with the covert-sarcopenia and muscle-strength-imbalance subtype associated with poorer multi-domain cognitive performance than high-metabolic-burden phenotypes, without establishing causality, resolving reverse causation or residual confounding, or demonstrating cognitive benefits from exercise. [human-observational] (novelty: 3)
- 2026-11-10 — Nutrition Care Strategies at the Intersection of Menopause and Obesity Pharmacotherapy.: [expert-opinion] Clinical nutrition review (no new primary data) identifies menopause-related estrogen decline and incretin-associated appetite suppression as potentially overlapping risks for inadequate intake, muscle loss, and bone loss, proposing protein optimization and targeted clinical care without establishing accelerated sarcopenic obesity or osteoporosis, or demonstrating prevention by these strategies. [expert-opinion] (novelty: 3)
- 2026-11-11 — Effects of henagliflozin proline tablets versus metformin extended-release tablets on body composition in geriatric patients with newly diagnosed type 2 diabetes mellitus (HABIT-GEMs): study protocol for a multicentre, randomised, open-label trial.: [human-rct; protocol only, no outcome data] HABIT-GEMs describes a multicentre, randomized, open-label non-inferiority trial comparing henagliflozin with metformin XR for appendicular skeletal muscle mass preservation in adults aged 60–85 with newly diagnosed type 2 diabetes, without yet establishing comparative muscle preservation, functional benefit, or prevention of sarcopenic obesity. [human-rct] (novelty: 3)
- 2026-09-01 — Impact of the Updated Asian Working Group for Sarcopenia 2025 Criteria on the Prevalence and Clinical Characteristics of Sarcopenic Obesity in Older Patients With Heart Failure.: [human-observational] Observational comparison in older patients with heart failure found that BMI adjustment under the updated AWGS 2025 criteria nearly doubled identified sarcopenic-obesity prevalence without improving mortality risk discrimination, demonstrating definition-sensitive classification rather than a causal change in risk or an exercise-treatment effect. [human-observational] (novelty: 3)
- 2026-11-01 — Discordance Between Height- and BMI-Adjusted AWGS 2025 Definitions of Confirmed Sarcopenia After Stroke.: [human-observational] Observational comparison in post-stroke patients reported more than 20% discordance between height- and BMI-adjusted AWGS 2025 confirmed-sarcopenia definitions, highlighting sensitivity to body-size normalization without establishing obesity-specific misclassification, diagnostic superiority, or equivalence to consensus-defined sarcopenic obesity. [human-observational] (novelty: 3)
- 2026-10-01 — Body composition changes in patients on GLP-1 receptor agonists undergoing an intensive cardiac rehabilitation program.: [human-observational] A clinical cohort of intensive cardiac rehabilitation participants found no statistically significant excess skeletal muscle mass loss in GLP-1 receptor agonist users versus non-users, without establishing equivalence, exercise-mediated muscle preservation, or effects on strength, function, or diagnosed sarcopenia. [human-observational] (novelty: 3)
- 2026-08-16 — Dynapenic obesity and incident cross-domain multimorbidity: A prospective study of three ageing cohorts.: [human-observational] Harmonized prospective analysis of CHARLS, HRS, and ELSA (n=15,207) associated dynapenic obesity with higher incident cross-domain multimorbidity, including more than three-fold risk of concurrent somatic disease, depressive symptoms, and cognitive impairment; this weakness-plus-obesity phenotype does not require low muscle mass and is not equivalent to consensus-defined sarcopenic obesity, while residual confounding and reverse causation remain unresolved. [human-observational] (novelty: 3)
- 2026-09-28 — Loss ofdisrupts lipid signaling and causes slow muscle fiber degeneration.: [animal-model] Model-organism loss-of-function study found that Srebp1 loss disrupted lipid mediator signaling and cardiolipin homeostasis, causing selective slow oxidative fiber degeneration and reduced muscle mass, without establishing an obesity-specific phenotype or relevance to human sarcopenic obesity. [animal-model] (novelty: 3)
- 2026-10-15 — Combined impact of dynapenic abdominal obesity on stroke risk in middle-aged and older adults: evidence from two nationwide prospective cohorts.: [human-observational] Two nationwide prospective cohorts (CHARLS and ELSA, total n>15,500; approximately seven-year follow-up) associated dynapenic abdominal obesity with roughly doubled incident stroke risk and higher risk than either weakness or abdominal obesity alone; this strength-plus-adiposity phenotype does not require low muscle mass and is not equivalent to consensus-defined sarcopenic obesity, while residual confounding and reverse causation remain unresolved. [human-observational] (novelty: 3)
- 2026-11-04 — GLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubes.: [mechanism-plausible] In vitro experiments in primary human myotubes found no induction of atrophy-related gene expression or impairment of myogenesis after direct semaglutide or GIP exposure under the tested conditions, arguing against direct myotoxicity in this model without establishing caloric restriction or unloading as the causes of clinical lean-mass loss or resolving effects on human strength and function. [mechanism-plausible] (novelty: 3)
- 2026-11-04 — Longitudinal associations between the hallmarks of aging and body composition: a narrative review.: [human-observational] Narrative review of 50 longitudinal human studies found that evidence linking aging hallmarks to muscle, bone, and adipose remodeling was concentrated in deregulated nutrient sensing and chronic inflammation, with major gaps for cellular senescence, epigenetic alterations, and autophagy; these associations do not establish causal drivers of sarcopenic obesity or demonstrate exercise-treatment effects. [human-observational] (novelty: 3)
- 2026-11-03 — Impact of sarcopenic obesity phenotype on long-term survival in geriatric trauma: A nationwide cohort study using weight-adjusted waist index.: [human-observational] Nationwide cohort (n=18,366; 20-year follow-up) reported an adjusted association between high Weight-Adjusted Waist Index (WWI) and 72% higher mortality in older adults after severe trauma; WWI is an anthropometric surrogate rather than a direct muscle-mass or strength assessment, and the study does not establish causality or resolve residual confounding, reverse causation, or the BMI obesity paradox. [human-observational] (novelty: 3)
- 2026-10-29 — Metabolic exhaustion underlies sarcopenic obesity susceptibility in aging mice as revealed by multi-omics factor analysis.: [animal-model] Multi-omics study in aging mice linked sarcopenic-obesity susceptibility to skeletal-muscle metabolic exhaustion and incomplete beta-oxidation rather than obesity severity, identifying circulating acetylcarnitine and pantothenol as candidate discriminators without establishing human biomarker validity or exercise-treatment effects. [animal-model] (novelty: 3)
- 2026-11-08 — Weaker or Just Lighter? Monitoring Strength and Function, Not Just Lean Mass, During GLP-1 Weight Loss.: [expert-opinion] Review (no new primary data) argues that lean-mass changes alone cannot establish functional deterioration during GLP-1 weight loss in older or high-risk adults, proposing objective strength and performance monitoring rather than demonstrating that GLP-1 therapy causes sarcopenia. [expert-opinion] (novelty: 3)
- 2026-10-26 — Skeletal Muscle in Vulnerable Populations Receiving Cardiorenal-Metabolic Therapies: SGLT2 Inhibitors, Incretin-Based Therapies, and the Challenge of Precision Medicine.: [expert-opinion] Review synthesizing human trial and observational evidence (no new primary data) describes SGLT2 inhibitor- and incretin-associated lean-mass reductions as proportional to overall weight loss without consistent strength or performance impairment, distinguishing lean-mass loss alone from clinical sarcopenia while retaining concern for vulnerable older adults. [expert-opinion] (novelty: 3)
- 2026-10-29 — Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.: Geriatrics 5Ms framework review (no new primary data) frames cardiometabolic benefits versus potential lean-mass loss and functional decline as a prescribing trade-off in older adults with obesity, emphasizing geriatric assessment rather than establishing that incretin therapy causes sarcopenia. [expert-opinion] [expert-opinion] (novelty: 3)
- 2026-09-28 — Opportunistic CT-Based Quantification of Myosteatosis: A Potent Universal Imaging Biomarker for Frailty and Mortality.: cross-connection with myosteatosis-thigh-fat-infiltration: A universal CT myosteatosis biomarker overlaps directly with the imaging definition of sarcopenic obesity, where low muscle attenuation plus adiposity drives risk. (novelty: 3)
- 2026-10-06 — The Effect of a Very Low-Carbohydrate Diet on Intermuscular Adipose Tissue and Muscle Function in Older Adults With Obesity.: cross-connection with myosteatosis-thigh-fat-infiltration: Weight-maintaining dietary composition change (very low-carb vs low-fat) altered thigh IMAT and function in older adults with obesity — a non-weight-loss lever on the sarcopenic-obesity phenotype. (novelty: 3)
- 2026-04-03 — EffectS of Lifestyle Interventions in Older PEople With Obesity (Effective SLOPE): a Systematic Review With Network Meta-Analyses.: cross-connection with resistance-training-sarcopenia: Effective SLOPE NMA strengthens the case that in older adults with obesity, resistance-inclusive exercise paired with nutrition and behavior-change beats single-lever approaches on function and fat mass while sparing fat-free mass — directly relevant to the sarcopenic-obesity intervention stack. (novelty: 3)
- 2026-06-09 — DXA-derived regional adiposity identifies hidden liver-metabolic risk beyond BMI in non-obese older adults: A cross-sectional study.: cross-connection with myosteatosis-thigh-fat-infiltration: DXA-derived low-muscle/high-VAT phenotype in non-obese older adults connects regional body-composition imaging to a sarcopenic-obesity-like risk pattern unmasked by BMI, bridging the fat-infiltration and sarcopenic-obesity literatures through a shared imaging-biomarker approach. (novelty: 3)
- 2026-06-27 — A prospective cohort study on the independent and combined effects of body mass status and grip strength on premature mortality risk among older adults.: cross-connection with grip-strength-gait-speed: UK Biobank cohort shows grip strength and EASO-defined body-mass categories combine multiplicatively for premature mortality — operationally the same strength-plus-adiposity axis that defines sarcopenic obesity, extended to an underweight-plus-weak-grip phenotype as the highest-risk combination. (novelty: 3)
- 2026-06-29 — Personalized blood flow restriction training at variable occlusion pressures improves multisystem function in overweight and obese older women.: cross-connection with blood-flow-restriction-training: Multi-system improvements from BFR in overweight/obese older women position occlusion training as a candidate low-load modality for sarcopenic-obesity populations where joint load and cardiometabolic constraints limit standard RT and aerobic prescriptions. (novelty: 3)
- 2026-08-20 — Effects of resistance training on balance-related physical performance in older adults with sarcopenic obesity: a systematic review and meta-analysis of randomized controlled trials.: cross-connection with resistance-training-sarcopenia: Pooled RCT evidence that standalone resistance training improves balance-related physical function (TUGT, SPPB) specifically in sarcopenic obesity links the RT-for-sarcopenia case to the sarcopenic-obesity phenotype page. (novelty: 3)
- 2026-09-30 — Sex- and age-specific patterns in bone, muscle, and fat across adulthood and their relation to osteosarcopenic adiposity phenotype: a cross-sectional study.: cross-connection with myosteatosis-thigh-fat-infiltration: Osteosarcopenic adiposity phenotype links IMAT trajectories to the bone-muscle-fat triad, extending sarcopenic obesity into a tri-compartment framework with earlier musculoskeletal decline. (novelty: 3)
- 2026-10-01 — Consensus-Defined Sarcopenic Obesity and a Related Dynapenic Obesity Phenotype in Relation to Early Cognitive Impairment.: Prospective cohort in non-demented older adults applying consensus sarcopenic-obesity criteria plus a dynapenic-obesity phenotype found both associated with poorer global cognition, memory, and attention over ~2 years — addresses prior definition heterogeneity by using the ESPEN/EASO consensus but remains associational. [human-observational] (novelty: 3)
Open questions
Related
Contributing findings
Weight, Fat Mass, and Lean Mass Changes After Bariatric Surgery and GLP-1-Based Therapy: A Systematic Review and Meta-Analysis.
13-nov-2026
novelty 3
per-area 2
mentions
Associations of short and long sleep duration with multiple adverse health outcomes among ageing adults in South Africa.
13-nov-2026
novelty 2
per-area 2
strengthens
Will sarcopenia preventative pharmacology ensure the long-term success of GLP-1-derived therapies?
12-nov-2026
novelty 3
per-area 3
strengthens
Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.
11-nov-2026
novelty 4
per-area 4
strengthens
Effects of henagliflozin proline tablets versus metformin extended-release tablets on body composition in geriatric patients with newly diagnosed type 2 diabetes mellitus (HABIT-GEMs): study protocol for a multicentre, randomised, open-label trial.
11-nov-2026
novelty 3
per-area 3
strengthens
Associations between sarcopenic obesity subtypes, cognitive function and neurodegenerative diseases risk in middle-aged and older adults.
10-nov-2026
novelty 3
per-area 3
strengthens
Nutrition Care Strategies at the Intersection of Menopause and Obesity Pharmacotherapy.
10-nov-2026
novelty 3
per-area 3
strengthens
Body recomposition in adults: mechanisms, modulators, and practical algorithms for simultaneous skeletal muscle mass gain and fat mass loss.
10-nov-2026
novelty 2
per-area 2
strengthens
Sarcopenic Obesity: Estimation of Prevalence and Identification of Clinical and Biological Determinants in a Population of Adult Obese Patients
10-nov-2026
novelty 2
per-area 2
mentions
Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes
09-nov-2026
novelty 3
per-area 3
strengthens
Weaker or Just Lighter? Monitoring Strength and Function, Not Just Lean Mass, During GLP-1 Weight Loss.
08-nov-2026
novelty 3
per-area 3
strengthens
GLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubes.
04-nov-2026
novelty 3
per-area 3
strengthens
Longitudinal associations between the hallmarks of aging and body composition: a narrative review.
04-nov-2026
novelty 3
per-area 3
strengthens
Impact of sarcopenic obesity phenotype on long-term survival in geriatric trauma: A nationwide cohort study using weight-adjusted waist index.
03-nov-2026
novelty 3
per-area 3
strengthens
Height, Weight, and BMI Muscle Mass Adjustment for Sarcopenic Obesity: Differential Associations with Functional Outcomes among Healthy Asian Older Adults.
02-nov-2026
novelty 2
per-area 2
strengthens
Discordance Between Height- and BMI-Adjusted AWGS 2025 Definitions of Confirmed Sarcopenia After Stroke.
01-nov-2026
novelty 3
per-area 3
strengthens
Possible sarcopenia, abdominal obesity, and all-cause mortality in middle-aged and older adults with chronic kidney disease: a dual-cohort study.
01-nov-2026
novelty 2
per-area 2
weakens
Metabolic exhaustion underlies sarcopenic obesity susceptibility in aging mice as revealed by multi-omics factor analysis.
29-oct-2026
novelty 3
per-area 3
strengthens
Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.
29-oct-2026
novelty 3
per-area 3
strengthens
Corrigendum to "Effect of aerobic or resistance exercise, or both on insulin secretion, ciliary neurotrophic factor, and insulin-like growth factor-1 in dieting older adults with obesity" [Clin Nutr 51 (2025) 50-62].
28-oct-2026
novelty 1
per-area 1
mentions
Differences in functional mobility and body composition between older Thai women with and without mild cognitive impairment: a cross-sectional comparative study.
27-oct-2026
novelty 2
per-area 2
strengthens
The use of glucagon-like peptide-1 agonists as a treatment for obesity in older people: risks and benefits.
27-oct-2026
novelty 2
per-area 2
strengthens
Skeletal Muscle in Vulnerable Populations Receiving Cardiorenal-Metabolic Therapies: SGLT2 Inhibitors, Incretin-Based Therapies, and the Challenge of Precision Medicine.
26-oct-2026
novelty 3
per-area 3
strengthens
Exploring Association Rules for Chronic Comorbidities in Possible Sarcopenic Obesity among Middle-aged and Older Adults: Evidence from the CHARLS 2015.
21-oct-2026
novelty 2
per-area 2
strengthens
Relative muscle mass and grip strength as complementary correlates of metabolic syndrome: a nationwide DXA-based study of Korean adults.
17-oct-2026
novelty 2
per-area 2
strengthens
Glucose-Lowering Therapies in Type 2 Diabetes-Associated Sarcopenia: Mechanisms, Clinical Evidence and a Muscle-Centred Framework.
17-oct-2026
novelty 3
per-area 3
strengthens
Combined impact of dynapenic abdominal obesity on stroke risk in middle-aged and older adults: evidence from two nationwide prospective cohorts.
15-oct-2026
novelty 3
per-area 3
strengthens
Body Composition, Physical Activity and Energy Requirements Estimated Using Two Isotopic Methods in Old and Adult Beagle Dogs.
13-oct-2026
novelty 2
per-area 2
strengthens
Prevalence and impact of sarcopenic obesity at hospital admission according to ESPEN-EASO approach on functional status of older adults: results of a retrospective and prospective observational study.
10-oct-2026
novelty 2
per-area 3
strengthens
[Sarcopenia, obesity, and limitations in daily activities in older adults from Elsi-Brazil: recommendations from the Sarcopenia Definition and Outcomes Consortium].
09-oct-2026
novelty 2
per-area 2
strengthens
Triglyceride-related metabolic indices and low relative muscle mass: a cross-sectional analysis of SMILE and NHANES.
07-oct-2026
novelty 2
per-area 2
strengthens
Digital Health Interventions for Weight Management in Older Adults with Overweight or Obesity: A Scoping Review.
07-oct-2026
novelty 2
per-area 2
strengthens
Optimizing health outcomes for older adults with sarcopenic obesity: a scoping review of nutrition, exercise and combined interventions.
07-oct-2026
novelty 2
per-area 2
strengthens
Body composition changes in patients on GLP-1 receptor agonists undergoing an intensive cardiac rehabilitation program.
01-oct-2026
novelty 3
per-area 3
strengthens
Association between anthropometric indices and serum liver enzyme levels in Iranian older adults: A cross-sectional study based on the Neyshabur Longitudinal Study on Ageing (NeLSA).
01-oct-2026
novelty 2
per-area 2
strengthens
Consensus-Defined Sarcopenic Obesity and a Related Dynapenic Obesity Phenotype in Relation to Early Cognitive Impairment.
01-oct-2026
novelty 3
per-area 3
strengthens
Loss ofdisrupts lipid signaling and causes slow muscle fiber degeneration.
28-sep-2026
novelty 3
per-area 3
strengthens
Impact of the Updated Asian Working Group for Sarcopenia 2025 Criteria on the Prevalence and Clinical Characteristics of Sarcopenic Obesity in Older Patients With Heart Failure.
01-sep-2026
novelty 3
per-area 3
strengthens
Reframing obesity in aging people with HIV: sarcopenic obesity, muscle quality, and frailty.
01-sep-2026
novelty 2
per-area 2
strengthens
Risk of protein intake deficiency during treatment with GLP-1 and GIP/GLP-1 receptor agonists: considerations for secondary sarcopenia.
22-aug-2026
novelty 2
per-area 2
strengthens
Aging-, obesity-, and diabetes-related sarcopenia: Pathogenesis and interventions.
20-aug-2026
novelty 2
per-area 2
strengthens
Dynapenic obesity and incident cross-domain multimorbidity: A prospective study of three ageing cohorts.
16-aug-2026
novelty 3
per-area 3
strengthens
Beyond Weight Loss: A Geriatric Perspective on GLP-1 RAs in Older Adults With Obesity.
04-jun-2026
novelty 2
per-area 2
mentions